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A B S T R A C T
The link between HDL subclasses and the prognosis of cardiovascular diseases remains controversial. We thus
evaluated the prognostic value of the HDL subclasses 3 and 2 cholesterol (HDL3-C, HDL2-C) as well as of total
HDL-C for 3-month mortality in acute heart failure (AHF) patients. The serum levels of HDL3-C and total HDL-C
were determined by detergent-based homogeneous assay. HDL2-C was computed by the difference between total
HDL-C and HDL3-C. Out of the 132 analyzed patients, 35 (26.5%) died within three months after onset of AHF.
Univariate logistic regression analyses revealed a significant inverse association of HDL3-C (odds ratio (OR) 0.46
per 1-SD increase, 95% confidence interval (CI) 0.27–0.72, p= 0.001) with 3-month mortality, whereas con-
centrations of total HDL-C and HDL2-C showed no significant association. After adjustment for various la-
boratory and clinical parameters known to be associated with mortality in heart failure patients, HDL3-C con-
centrations remained significantly associated with 3-month mortality (OR 0.34 per 1-SD increase, 95% CI
0.15–0.74, p=0.010). We conclude that low admission serum levels of HDL3-C are associated with an increased
3-month mortality in AHF patients, whereas total HDL-C and HDL2-C showed no association. HDL3-C might thus
be useful as a prognostic parameter in AHF.
1. Introduction
Heart failure (HF) is a frequent cause of morbidity and mortality
worldwide [1]. Being a final stage of various cardiovascular diseases,
HF is defined by the European Society of Cardiology (ESC) as an ab-
normality of the cardiac structure and function, resulting in a dimin-
ished ability of the heart to maintain optimal perfusion of metabolizing
tissues [2,3]. Acute heart failure (AHF) denotes the rapid onset of, or
changes in, symptoms and signs of HF [3].
Previous studies have demonstrated the capacity of HDL to inhibit
mechanical stress-induced cardiomyocyte autophagy and cardiac
hypertrophy [4], improve cell survival, preserve mitochondrial func-
tion, attenuate oxidative stress [5,6], and promote glucose uptake by
cardiomyocytes [7]. HDL is a potent inducer of endothelial NO pro-
duction [8], which promotes relaxation of the coronary arteries and, in
turn, perfusion of the failing heart. Additionally, HDL-induced NO
might contribute to the maintenance of the physiological titin phos-
phorylation and normal cardiomyocyte tension [9].
It is important to note that HDL particles comprise two major sub-
classes, namely large buoyant HDL2 particles and smaller, denser HDL3
particles. Accordingly, quantity of the total HDL-C is dominated by the
contribution of the larger, cholesterol-rich HDL2. This results in an
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inadequately low contribution of the smaller, denser, cholesterol-poor
HDL3, whose cardioprotective activities are superior to that of HDL2
[10,11]. Indeed, recent studies revealed that serum levels of cholesterol
in the HDL3 subclass (HDL3-C) are predictive of cardiovascular events
and that the HDL3 subclass may be primarily responsible for the inverse
association of HDL-C and cardiovascular disease [12–15]. Clinical stu-
dies have shown that assessing circulating concentrations of HDL par-
ticles (HDL-P) by NMR spectroscopy is superior to HDL-cholesterol in
predicting cardiovascular risk [16].
2. Theory
We have shown in our previous study that low serum concentrations
of small but not large HDL-P, quantified by NMR spectroscopy, are
associated with increased 3-month mortality in AHF patients [17].
Considering that small HDL-P may primarily represent the HDL3 sub-
class, we hypothesized that the serum levels of HDL3-C might have a
prognostic capacity for mortality in AHF. In contrast to the quantifi-
cation of HDL-P by NMR spectroscopy, the HDL subclasses can be
measured by a simple and convenient method on automated analyzers
in routine clinical laboratories. We therefore aimed to assess the asso-
ciations of the concentrations of the HDL subclasses with 3-month
mortality in AHF.
3. Material and methods
3.1. Study design and patients
Study design, inclusion and exclusion criteria as well as patient
characteristics for our AHF cohort have been described in our previous
reports [17–20]. In brief, we performed a prospective observational
study including consecutive hospitalized AHF patients. Written in-
formed consent was obtained from each patient and the study was
conducted in adherence to the ethical guidelines of the Declaration of
Helsinki [21]. The study was approved by the Ethics Committees of the
University Hospital Centre Sisters of Charity, Zagreb, Croatia and the
Medical University of Graz, Austria. All patients were treated according
to the European Society of Cardiology (ESC) Guidelines for AHF [3,22].
3.2. Laboratory assays
The collection of the blood samples, the standard laboratory
methods and measurements of small, large and total HDL-P have been
described in previous reports on our AHF cohort [17–20,23]. The levels
of total HDL cholesterol (HDL-C) and HDL3-C were measured using
homogeneous assays from Denka Seiken Co., Ltd. (Tokyo, Japan) [24]
on an Olympus AU680 automated analyzer. HDL2-C was estimated by
subtracting HDL3-C from total HDL-C.
3.3. Statistical analysis
Differences in the serum levels of HDL3-C, HDL2-C, and total HDL-C
between groups according to various patient characteristics were tested
with the Mann-Whitney U test. Correlations between HDL3-C, HDL2-C,
and total HDL-C and various laboratory and clinical parameters were
determined by the Spearman correlation coefficient due to the skewed
distribution of many of the laboratory parameters. Because of multiple
comparisons for these analyses, we applied a Bonferroni correction to
the significance level: for the correlation analyses (18 parameters) a p-
value of< 0.003 and for group differences (6 parameters) a p-value
of< 0.008 was considered significant. Furthermore, univariable and
multivariable logistic regression analyses were used to examine the
impact of HDL3-C, HDL2-C, and total HDL-C on 3-month mortality. In
the multivariable analyses, we adjusted for age, sex, N-terminal pro-
brain natriuretic peptide (NT-proBNP), glomerular filtration rate (GFR),
mean arterial pressure (MAP), low-density lipoprotein (LDL)-
cholesterol, log(triglycerides), type 2 diabetes (T2D), and C-reactive
protein (CRP). Results are presented as odds ratio (OR) and the re-
spective 95% confidence interval (CI) per standard deviation (SD) in-
crease. R version 3.4.4 was used for these analyses.
4. Results
4.1. Patients' clinical characteristics, medication and laboratory parameters
The baseline characteristics, comorbidities, medication, laboratory
results, and outcome of our 152 AHF patients have been described
elsewhere [17–20]. Serum samples of 132 patients [65 (49.2%) were
female and median and range for age were 77.3 (45.5–92.4) years],
were available for the analyses presented here. Of these, 35 (26.5%)
died within three months of onset of AHF. Median and range for serum
levels of HDL3-C, HDL2-C, and total HDL-C were 0.49 (0.23–0.85)
mmol/L, 0.62 (0.19–1.67) mmol/L and 1.13 (0.42–2.46) mmol/L, re-
spectively. Clinical characteristics, medication and laboratory para-
meters of patients who died compared to those who were alive the first
three months after onset of AHF are shown in supplemental Tables S1
and S2.
4.2. Correlation of HDL3-C, HDL2-C and total HDL-C concentrations with
laboratory and clinical variables
The serum levels of HDL3-C and total HDL-C, but not of HDL2-C,
were significantly positively correlated with MAP and negatively with
urea and CRP after the Bonferroni correction (Table 1). Furthermore,
HDL3-C was significantly negatively correlated with systolic pulmonary
artery pressure (SPAP) and NT-proBNP and positively with platelets.
HDL-C was solely significantly negatively correlated with creatinine
(Table 1).
4.3. Correlation of HDL3-C, HDL2-C and total HDL-C concentrations with
small, large, and total HDL-P
The serum levels of HDL3-C showed a strong positive correlation
with total and small HDL-P, as well as a weak positive correlation with
large HDL-P (Fig. 1). In contrast, concentrations of HDL2-C showed a
strong positive correlation with large HDL-P, a moderate positive cor-
relation with total HDL-P, and no significant correlation with small
HDL-P. Finally, the serum levels of total HDL-C showed a moderate
positive correlation with the total, and large HDL-P, and a moderate
positive correlation with small HDL-P.
4.4. Levels of HDL3-C, HDL2-C, and total HDL-C compared between
different subgroups of AHF patients
As shown in Table 2, after the Bonferroni correction the levels of
HDL3-C, but not of total HDL-C and HDL2-C, were significantly lower in
AHF patients with worsening of chronic HF compared to de novo AHF
patients, in AHF patients with one or more signs implying venous vo-
lume overload (jugular venous distension, enlarged liver, peripheral
edema or ascites), and in patients that died within three months after
onset of AHF. The levels of HDL3-C, but not of HDL-C and HDL2-C,
were higher in patients with hypercholesterolemia. In contrast, AHF
patients with T2D had significantly lower total HDL-C and HDL2-C, but
similar HDL3-C, levels when compared to AHF patients without T2D.
4.5. Logistic regression analyses
To study association of HDL subclasses with mortality logistic re-
gression analyses were performed. Univariate analyses revealed a sig-
nificant inverse association of 3-month mortality and the serum con-
centrations of HDL3-C, but showed no association with the total HDL-C
and HDL2-C concentrations (Table 3). Importantly, the concentrations
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of HDL3-C remained significantly associated with 3-month mortality
after adjusting for age, sex, NT-proBNP, GFR, MAP, LDL cholesterol, log
(triglycerides), T2D, and CRP the clinical and laboratory parameters
that are known to be associated with mortality in HF patients (Table 3).
5. Discussion
Although several studies examined the association between the
outcome and prognosis in HF and HDL-cholesterol [25–27] our study is
the first to address the association of the HDL subclasses with mortality
in AHF.
Here we show for the first time that a low concentration of cho-
lesterol in circulating HDL3 particles, but not in HDL2 or total HDL, is
associated with increased 3-month mortality of AHF patients.
Considering that HDL3-C may reflect the cholesterol content of small
HDL-P and HDL2-C that of large HDL-P, the present finding is fully in
line with our previous results showing that only the concentrations of
small HDL-P were associated with mortality, whereas the concentra-
tions of large HDL-P and total HDL-C were not [17]. Indeed, in the
present study we found a strong correlation between HDL3-C and small
HDL-P as well as between HDL2-C and large HDL-P. Due to its simpli-
city and operability on automated analyzers that are available in rou-
tine clinical laboratories, measurement of HDL3-C is applicable in daily
clinical practice. This is not the case with NMR-based measurements of
HDL particle concentrations, a method requiring special instrumenta-
tion that is available only in some routine clinical laboratories.
Our results appear to be in line with recent studies showing that the
serum levels of HDL3-C are predictive of cardiovascular events and that
the HDL3 subclass may be primarily responsible for the inverse asso-
ciation between HDL-C and cardiovascular disease [12–15].
Several studies examined the association of the outcome and prog-
nosis in HF with HDL-C [25–27]. However, as mentioned above, no
study has examined the prognostic capacity of HDL3-C concentrations
for mortality in AHF so far. In the present study, we observed a strong
independent association of low levels of the HDL subclass 3 but not of
HDL2 with mortality, suggesting cardiovascular protective activities of
the former subclass. Our results are in good agreement with previous
studies showing that anti-oxidative enzymes as well as particular lipid
species entailing cardiovascular protective activities are enriched in
HDL3 subclass [10,11].
Interestingly, the serum concentrations of HDL3-C, but not of HDL2-
C or total HDL-C, were negatively correlated with NT-proBNP sug-
gesting a sensitivity of HDL3-C to the severity of the AHF pathophy-
siology. Furthermore, only HDL3-C, but not HDL2-C or total HDL-C,
was negatively correlated with SPAP, whose elevation reflects left
ventricular dysfunction, heart congestion, and elevated left-sided filling
pressure accompanied by increased NT-proBNP [28].
A more pronounced negative impact of the AHF pathophysiology on
HDL3-C, compared to HDL2-C, is also illustrated by the lower levels of
HDL3-C, but not of HDL2-C, in AHF patients with a more severe state of
the disease, namely worsening of chronic HF, compared to de novo AHF
patients [20]. Additionally, the levels of HDL3-C were lower in AHF
patients with sign(s) implying venous congestion, a consequence of
right-sided heart failure, as compared to patients without these signs.
In the present study, the serum levels of HDL3-C, but not of HDL2-C
or total HDL-C, were (borderline significantly; p=0.003) positively
correlated with the serum levels of total proteins, the markers of nu-
tritional status and liver biosynthetic capacity. Accordingly, our data
suggest that only the serum levels of HDL3-C are affected by alterations
in the biosynthetic capacity of the liver, which in HF is frequently de-
creased due to hypoperfusion and congestion [29]. This may, at least in
part, explain why the serum levels of HDL3-C, but not of HDL2-C or
total HDL-C, were lower in AHF patients with venous congestion, as
compared to patients without.
It is well established that the augmented translocation of bacterial
endotoxins from the edematous intestine into the circulation [30], as
well as the pro-inflammatory activation of venous endothelial cells due
to congestion, contribute to the chronic inflammation in HF [31], re-
sulting in increased formation and clearance of leukocyte - platelet
complexes [32]. Considering the role of circulating lipoproteins in the
binding and neutralization of endotoxines [33], a negative correlation
of HDL3-C with CRP, as well as a positive correlation with platelets,
might reflect the counteraction of an inflammatory response by HDL3.
Alternatively, the observed correlations between HDL3-C and the in-
flammatory markers might be a consequence of the opposite regulation
of HDL3-C and the inflammatory molecules by the AHF pathophy-
siology. A similar effect might also explain the negative correlations of
HDL3-C, HDL2-C, and total HDL-C with the markers of kidney function,
Table 1
Correlation analyses of HDL3-C, HDL2-C, and total HDL-C with clinical and laboratory parameters.
HDL3-C (mmol/L) HDL2-C (mmol/L) Total HDL-C (mmol/L)
r p-Value r p-Value r p-Value n
Age (years) −0.12 0.166 0.11 0.189 0.02 0.843 132
BMI (kg/m2) 0.03 0.728 −0.24 0.005 −0.15 0.091 132
MAP (mmHg) 0.44 <0.001 0.25 0.003 0.33 <0.001 132
SPAP (mmHg) −0.36 0.002 −0.13 0.282 −0.21 0.063 76
Heart rate (beats/min) 0.22 0.011 0.15 0.082 0.18 0.036 132
NT-proBNP (pg/ml) −0.28 0.001 −0.03 0.781 −0.13 0.162 126
GFR (ml/min/1.73m2) 0.23 0.007 0.13 0.137 0.19 0.029 131
Urea (mmol/L) −0.31 <0.001 −0.21 0.014 −0.27 0.002 131
Creatinine (μmol/L) −0.25 0.004 −0.24 0.005 −0.27 0.002 131
ALT (U/L) 0.07 0.443 0.03 0.719 0.03 0.772 128
AST (U/L) −0.08 0.386 0.08 0.351 0.03 0.760 129
Protein (g/L) 0.26 0.003 0.05 0.556 0.13 0.146 129
Fibrinogen (g/L) 0.20 0.021 −0.01 0.873 0.08 0.394 127
Albumin (g/L) 0.17 0.058 −0.01 0.902 0.04 0.679 129
IL-6 (pg/mL) −0.21 0.016 −0.04 0.617 −0.09 0.312 132
CRP (μg/mL) −0.31 <0.001 −0.22 0.011 −0.27 0.002 130
Leukocytes (×109/L) 0.22 0.010 0.10 0.278 0.16 0.074 131
Platelets (×1012/L) 0.32 <0.001 0.16 0.072 0.24 0.006 132
Data presented are the Spearman correlation coefficient r, the corresponding p-values, and the number of available samples (n);
P- values of< 0.003 are considered significant after a Bonferroni correction for multiple comparison and are depicted in bold.
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; CRP, C-reactive protein; GFR, glomerular filtration rate; HDL-C, high-density
lipoprotein cholesterol; IL-6, interleukin 6; LDL, low-density lipoprotein; MAP, mean arterial pressure; NT-proBNP, N-terminal pro brain natriuretic peptide; SPAP,
systolic pulmonary artery pressure.
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which is frequently impaired in HF [34].
The positive correlation of HDL3-C, HDL2-C (borderline significant;
p=0.003), and total HDL-C with MAP might reflect their negative
regulation by the AHF pathophysiology. Alternatively, a better tissue
perfusion in patients with higher MAP might conceivably, similar as
endurance training [35], raise serum HDL levels.
In the present study, we observed that the concentrations of total
HDL-C and HDL2-C, but not of HDL3-C, were lower in AHF patients
with T2D compared to those without. This is in line with results of a
previous study demonstrating that insulin resistance and adiposity af-
fect lipoprotein size and the subclass concentrations in the general
population [36].
The association of decreased HDL3-C serum levels with an increased
mortality in our AHF cohort raises the question of whether HDL3-C is
only a marker of the disease severity or an active counteractor of the
detrimental underlying pathophysiology. Considering the numerous
beneficial effects of HDL on the cardiovascular system, several potential
HDL3-dependent mechanisms might contribute to the improvement of
the patients' overall status and thus to a decreased mortality in AHF.
Circulating HDL3 particles may exert a direct positive effect on the
failing heart, such as improving cell survival, preserving mitochondrial
function, attenuating oxidative stress [5,6], as well as promoting glu-
cose uptake by cardiomyocytes [7], and stimulating endothelial NO
production [8]. Indeed, it has been shown recently that raising HDL
serum levels by overexpression of apoA-I, a major protein constituent of
HDL, reduces cardiac hypertrophy and myocardial fibrosis, and
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Fig. 1. Correlation of HDL3-C, HDL2-C, and total HDL-C concentrations with small, large, and total HDL-P. Correlations of HDL3-C, HDL2-C, and total HDL-C with
small, large, and total HDL-P were determined using the Spearman correlation coefficient. HDL-P, concentrations of HDL particles.
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improves cardiac function in mice with chronic pressure overload [37].
A previous study has shown that the cholesterol content per HDL-P,
calculated as the ratio of HDL-C to HDL-P concentration, is in-
dependently associated with progression of carotid atherosclerosis in a
cardiovascular disease-free population [38]. In the present study lo-
gistic regression analyses revealed a significant positive association of
the ratio of total HDL-C to total HDL-P and HDL3-C to small HDL-P, but
a significant negative association of the ratio of HDL2-C to large HDL-P
with 3-month mortality (Supplemental Table S3). The associations did
not remain significant upon adjustment for parameters associated with
mortality in HF (Supplemental Table S3). Nevertheless, these data
suggest that in AHF, cholesterol overload of small HDL-P renders the
particles detrimental and therefore associated with increased mortality,
whereas the opposite is the case with large HDL-P.
It remains to be determined whether an HDL raising therapy with
niacin or cholesterol ester transfer protein inhibitors would affect the
incidence of HF and the mortality rate in AHF patients.
There are several limitation to our present study: The design pre-
cludes drawing conclusions about cause and effect for the relationship
between HDL and other laboratory and clinical parameters.
Accordingly, we can only suggest a link between the serum levels of
cholesterol in the HDL subclasses and the pathophysiologic processes in
our patients. Therefore, we cannot provide a mechanistic explanation
on how HDL3-C levels might affect mortality. Furthermore, in the
present study HDL3-C was more strongly correlated with total than
with small HDL-P. This, together with the limited specificity of homo-
genous assays, in particular in dyslipidemic samples, precludes the in-
terpretation that HDL3-C reflects exclusively small HDL particles. In
addition, having measured the cholesterol content in the HDL sub-
classes only at admission we are unable to address the relationship of
changes in these parameters with the outcome. Finally, the moderate
number of available serum samples (n=132) in this monocentric study
influences the statistical power of our analyses. Therefore, further and
larger studies are needed to confirm our results.
6. Conclusions
We conclude that low admission serum levels of HDL3-C are asso-
ciated with an increased 3-month mortality in AHF patients and that
HDL3-C might thus be useful as a prognostic parameter in AHF.
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Table 2
HDL3-C, HDL2-C, and total HDL-C levels in various groups of AHF patients.
HDL3-C (mmol/L) HDL2-C (mmol/L) Total HDL-C (mmol/L) n
Sex Male 0.48 (0.23–0.85) 0.59 (0.19–1.30) 1.04 (0.42–1.83) 67
Female 0.50 (0.27–0.82) 0.69 (0.30–1.67) 1.19 (0.57–2.46) 65
p=0.733 p=0.024 p=0.095
AHF type De novo 0.54 (0.32–0.85) 0.64 (0.33–1.48) 1.24 (0.70–2.30) 40
Worsening of CHF 0.46 (0.23–0.79) 0.61 (0.19–1.67) 1.05 (0.42–2.46) 92
p < 0.001 p=0.115 p=0.017
Sign(s) No 0.57 (0.33–0.85) 0.62 (0.33–1.25) 1.22 (0.75–2.03) 28
Yes 0.46 (0.23–0.82) 0.62 (0.19–1.67) 1.09 (0.42–2.46) 104
p=0.001 p=0.555 p=0.089
T2D No 0.51 (0.23–0.82) 0.70 (0.35–1.67) 1.22 (0.63–2.46) 60
Yes 0.47 (0.23–0.85) 0.59 (0.19–1.09) 1.03 (0.42–1.59) 71
p=0.210 p=0.002 p=0.007
HypChol No 0.46 (0.23–0.69) 0.62 (0.19–1.44) 1.09 (0.42–1.94) 81
Yes 0.53 (0.23–0.85) 0.61 (0.30–1.67) 1.21 (0.57–2.46) 51
p < 0.001 p=0.516 p=0.070
Three months after onset of AHF Alive 0.51 (0.26–0.85) 0.62 (0.20–1.48) 1.17 (0.46–2.30) 92
Dead 0.41 (0.23–0.79) 0.55 (0.19–1.67) 0.99 (0.42–2.46) 35
p < 0.001 p=0.215 p=0.023
Data are presented as median and range (minimum to maximum). Differences in the serum levels of HDL3-C, HDL2-C, and HDL-C between the groups were tested
with the Mann-Whitney U test.
P-values of< 0.008 are considered significant after a Bonferroni correction for multiple comparison and are depicted in bold.
AHF, acute heart failure; CHF, chronic heart failure; HDL-C, high-density lipoprotein cholesterol; HypChol, hypercholesterolemia; Signs include enlarged liver,
peripheral edemas, ascites and jugular venous distension.
Table 3
Univariable and multivariable logistic regression analyses of 3-month mortality for HDL3-C, HDL2-C, and total HDL-C.
Unadjusted Adjusteda
OR (95% CI) p-value OR (95% CI) p-value
HDL3-C (mmol/L) 0.46 (0.27–0.72) 0.001 0.34 (0.15–0.74) 0.010
HDL2-C (mmol/L) 0.89 (0.57–1.33) 0.528 0.72 (0.39–1.30) 0.283
Total HDL-C (mmol/L) 0.70 (0.44–1.05) 0.099 0.59 (0.30–1.09) 0.101
OR and CI are presented on the SD scale (increase per 1 SD); SDs for HDL3-C, HDL2-C, and total HDL-C are 0.13, 0.26, and 0.36mmol/L, respectively.
Data of 127 patients (35 events) were available for the unadjusted analyses and data of 118 patients (33 events) for the adjusted analyses.
Significant results are depicted in bold.
CI, confidence interval; CRP, C-reactive protein; GFR, glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; LDL, low-density lipoprotein; MAP,
mean arterial pressure; NT-proBNP, N-terminal pro brain natriuretic peptide; OR, odds ratio; SD, standard deviation; T2D, type 2 diabetes.
a The model was adjusted for age, sex, NT-proBNP, GFR, MAP, LDL-cholesterol, log(triglycerides), T2D, and CRP.
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